Navigation Links
A scientific breakthrough on the control of the bad cholesterol
Date:11/24/2008

Montral, November 24, 2008 A study performed by the team of Dr. Nabil G. Seidah, Director of the Biochemical Neuroendocrinology Research Unit at the IRCM, shows for the very first time that the degradation by PCSK9 of the LDLR receptor, which is responsible for removing the bad cholesterol (LDL-cholesterol) from the bloodstream, may be inhibited by a third protein, annexin A2. This major discovery co-authored by Gatan Mayer, a postdoctoral fellow, Steve Poirier, a doctoral student, and Dr. Seidah was published on November 14 in the Journal of Biological Chemistry (JBC).

Genetic studies on humans have clearly shown that PCSK9 is a prime therapeutic target for the prevention and treatment of cardiovascular diseases. PCSK9 proprotein convertase promotes the degradation of the receptor responsible for eliminating LDL-cholesterol particles. Thus, the presence of PCSK9 leads to a surplus of bad cholesterol in the bloodstream and contributes to plaque formation, leading to blockage of blood vessels and arteries. This phenomenon is a major risk factor that can lead to cardiovascular diseases, such as heart attack, atherosclerosis and stroke. Mutations of human genes have demonstrated that a rise in PCSK9 activity results in a major increase in LDL-cholesterol and familial hypercholesterolemia. Conversely, in people with a non-functional mutation in the gene coding for PCSK9, a decrease in its activity brings down the LDL-cholesterol concentration levels in the bloodstream and diminishes by up to 88% the risks of developing cardiovascular diseases.

"By performing a series of biochemical experiments, we discovered that annexin A2 binds strongly to PCSK9 and inhibits its function," remarks Gatan Mayer, the article's first author. This discovery should pave the way toward the development of a new drug that would lower blood cholesterol to recommended levels. Currently, cholesterol lowering drugs known as "statins" are used by more than 25 million people worldwide. Statins decrease cholesterol synthesis and increase the number of LDL-receptors, thus efficiently decreasing plasma cholesterol levels; however, they also increase the amount of PCSK9, which degrades those receptors, thus reducing the effect of statins. A drug that would block PCSK9 could either be used alone or jointly with statins and would be highly beneficial to patients in whom statins do not work or are unable to take this drug.


'/>"/>

Contact: Nabil G. Seidah
seidahn@ircm.qc.ca
514-987-5609
Institut de recherches cliniques de Montreal
Source:Eurekalert

Related biology news :

1. Barrow scientists solve 200-year-old scientific debate involving visual illusions
2. Scientific community called upon to resolve debate on net energy once and for all
3. Top scientific meeting urges coordinated response to economic and environmental crises
4. Loggerhead release to provide vital information to scientific community
5. NIAID scientists to speak on range of infectious disease topics at major scientific meeting
6. ETH Zurich-administered fund ends scientific anonymity
7. Gene therapy anti-cancer research featured in Scientific American
8. In scientific first, Einstein researchers correct decline in organ function associated with old age
9. The emerging scientific discipline of aeroecology
10. Significant impact factor boost for scientific journal Genome Research
11. Scientific information largely ignored when forming opinions about stem cell research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)... Feb. 3, 2016 ... of the "Emotion Detection and Recognition ... and Others), Software Tools (Facial Expression, Voice ... Users,and Regions - Global forecast to 2020" ... --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced the ...
(Date:2/2/2016)... Checkpoint Inhibitors for Cancer – Explore ... you interested in the future of cancer drugs? ... Visiongain,s report gives those predictions to 2026 at ... Avoid falling behind in data or losing ... those emerging cancer therapies can achieve. There you ...
(Date:2/2/2016)... Feb. 2, 2016  Based on its recent ... Sullivan recognizes US-based Intelligent Retinal Imaging Systems (IRIS) ... Award for New Product Innovation. IRIS, a prominent ... North America , is poised to set ... diabetic retinopathy market. The IRIS technology presents superior ...
Breaking Biology News(10 mins):
(Date:2/3/2016)... 3, 2016  With the growing need for ... is underway, therapies such as monoclonal antibodies, recombinant ... host of indications are in high demand. Conventionally ... development and production of these therapeutics. However, due ... high costs, novel approaches and novel expression systems ...
(Date:2/3/2016)... Feb. 3, 2016 Harvard Apparatus Regenerative ... company developing bioengineered organ implants for life-threatening conditions ... that CEO Jim McGorry , will present ... on Tuesday, February 9, 2016 at 8:00 ... . HART,s presentation will be webcast live ...
(Date:2/3/2016)... ... February 03, 2016 , ... Aerocom, a world-leading supplier of ... North American healthcare market. , Aerocom Healthcare, LLC will be based in Denver, ... provide new pneumatic tube systems or expand existing systems within the U.S. and ...
(Date:2/3/2016)... ... 03, 2016 , ... StarNet Communications Corp, ( http://www.starnet.com/ ) ... addition of a powerful “Session Preview” feature to its FastX remote Linux visualization ... remote Linux desktop or other applications (sessions) they have running on a remote ...
Breaking Biology Technology: